GLP-1 Receptor Agonist in Primary Intracerebral Hemorrhage: A Phase 2 Randomized Trial

A phase 2 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 200 participants.

Also called NCT07613437

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 200 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07613437
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China, Hong Kong SAR China (from the registry)
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT07613437. Randomized; no masking; primary purpose treatment. Start 2026-06-15 (anticipated); primary completion 2028-06-14 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
GLP-1 Receptor Agonist in Primary Intracerebral Hemorrhage: A Phase 2 Randomized Trial
Acronym
GLICH
Condition
Intracerebral Hemorrhage
Intervention (Drug)
Semaglutide, 0.5 mg/mL
Lead sponsor
Chinese University of Hong Kong (class: other)
Collaborator
The First Affiliated Hospital of University of Science and Technology of China (class: other)
Collaborator
First Affiliated Hospital of Wenzhou Medical University (class: other)

Record details

Record id
cardio:ct-nct07613437
Content hash
24f198c5bdc4a12e89ddc9947a7d58577d502b7b7a2606a40aa56a59d989e369